# A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

> **NCT06913218** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 60 (estimated)

## Conditions studied

- Pancreas Cancer
- Pancreas Cancer, Duct Cell Adenocarcinoma

## Interventions

- **BIOLOGICAL:** AK154
- **BIOLOGICAL:** Cadonilimab
- **BIOLOGICAL:** Ivonescimab (SMT112 or AK112) Injection
- **DRUG:** mFOLFORINOX

## Key facts

- **NCT ID:** NCT06913218
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2028-02-23
- **Final completion:** 2028-11-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06913218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06913218, "A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06913218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*